Martin Almquist
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin Almquist has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Anders Bergenfelz
Department of Clinical Sciences, Lund University , 221 84 Lund
7 shared publications - Lars Rolighed
Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital, Aarhus, Denmark
5 shared publications - Mark Thier
Department of Clinical Sciences, Lund University , 221 84 Lund
5 shared publications - Naomi Clyne
Lund University, Skåne University Hospital, Faculty of Medicine, Department of Clinical Sciences Lund , Nephrology, Lund
5 shared publications Erik Nordenström
Department of Surgery Skåne University Hospital Lund Lund Sweden
4 shared publications- Erik Nordenström
Department of Clinical Sciences, Lund University , 221 84 Lund
4 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (5)
Surgery versus observation in patients 65 years or older with primary hyperparathyroidism: randomized clinical trial
Background: A substantial portion of surgically treated patients with primary hyperparathyroidism (pHPT) are older than 65 years. The indication for parathyroidectomy in older patients with pHPT and mild hypercalcaemia is unclear. Specifically, it is not known whether parathyroid surgery improves bone mineral density (BMD) in this age group. Method: Patients 65 years or older with pHPT, ionized calcium not exceeding 1.50 mmol/l, and a BMD Z-score above −2.5 standard deviations who were referred to the Department of Surgery, Lund University Hospital, were included in the study. Follow-up was performed over 2 years. The random allocation sequence to surgery or observation was computer generated. There was no blinding. Primary outcome was BMD of the hip, with the primary endpoint being the change in total hip BMD from baseline to the end of follow-up. Secondary outcome was BMD of the lumbar spine. Continuous variables were analysed using Satterthwaite’s t-test. Intention-to-treat analysis of change from baseline was performed using a mixed-model repeated-measures ANOVA (MMRM ANOVA). Results: A total of 255 patients were screened and 102 were randomized: 50 to observation and 52 to surgery. The median age was 71 (range 65–85) years. For analysis of the primary endpoint, 41 patients in the surgery group and 40 in the observation group were available. Total hip BMD at 2 years increased by a mean of 1.3% (95% confidence interval −0.2% to 2.8%) in the surgery group and decreased by a mean of −1.4% (−2.6% to −0.2%) in the control group (P = 0.006). Analysis of total hip BMD at the end of follow-up by MMRM ANOVA showed a difference between the two groups of patients (P = 0.006). BMD of the lumbar spine increased by a mean of 4.6% (3.0% to 6.1%) in the surgery group versus 0.2% (−1.1% to 1.4%) in the observation group (P < 0.001). Analysis of lumbar spine BMD at the end of follow-up by MMRM ANOVA showed a difference between the two groups of patients (P < 0.001). Conclusion: At the 2-year follow-up, patients 65 years or older with pHPT and mild hypercalcaemia demonstrated a slight increase in BMD after parathyroidectomy. Registration number: NCT01087619 (http://www.clinicaltrials.gov).
- 4 September 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (5)
Open AccessSurgery versus observation in patients 65 years or older with primary hyperparathyroidism: randomized clinical trial
Background: A substantial portion of surgically treated patients with primary hyperparathyroidism (pHPT) are older than 65 years. The indication for parathyroidectomy in older patients with pHPT and mild hypercalcaemia is unclear. Specifically, it is not known whether parathyroid surgery improves bone mineral density (BMD) in this age group. Method: Patients 65 years or older with pHPT, ionized calcium not exceeding 1.50 mmol/l, and a BMD Z-score above −2.5 standard deviations who were referred to the Department of Surgery, Lund University Hospital, were included in the study. Follow-up was performed over 2 years. The random allocation sequence to surgery or observation was computer generated. There was no blinding. Primary outcome was BMD of the hip, with the primary endpoint being the change in total hip BMD from baseline to the end of follow-up. Secondary outcome was BMD of the lumbar spine. Continuous variables were analysed using Satterthwaite’s t-test. Intention-to-treat analysis of change from baseline was performed using a mixed-model repeated-measures ANOVA (MMRM ANOVA). Results: A total of 255 patients were screened and 102 were randomized: 50 to observation and 52 to surgery. The median age was 71 (range 65–85) years. For analysis of the primary endpoint, 41 patients in the surgery group and 40 in the observation group were available. Total hip BMD at 2 years increased by a mean of 1.3% (95% confidence interval −0.2% to 2.8%) in the surgery group and decreased by a mean of −1.4% (−2.6% to −0.2%) in the control group (P = 0.006). Analysis of total hip BMD at the end of follow-up by MMRM ANOVA showed a difference between the two groups of patients (P = 0.006). BMD of the lumbar spine increased by a mean of 4.6% (3.0% to 6.1%) in the surgery group versus 0.2% (−1.1% to 1.4%) in the observation group (P < 0.001). Analysis of lumbar spine BMD at the end of follow-up by MMRM ANOVA showed a difference between the two groups of patients (P < 0.001). Conclusion: At the 2-year follow-up, patients 65 years or older with pHPT and mild hypercalcaemia demonstrated a slight increase in BMD after parathyroidectomy. Registration number: NCT01087619 (http://www.clinicaltrials.gov).
- Open Access
- 27 July 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Indocyanine green fluorescence during total thyroidectomy: utility for predicting hypoparathyroidism and safety assessment
Purpose: Parathyroid fluorescence with indocyanine green (ICG) might prevent and predict postoperative hypoparathyroidism (hypoPT) after total thyroidectomy (TT). We aimed to evaluate parathyroid gland vascularization with ICG during TT. Further, we aimed to evaluate safety of ICG fluorescence and to correlate changes in PTH with postoperative hypoPT after TT. Methods: From May 2021 to June 2023, consecutive patients underwent TT and parathyroid fluorescence with ICG. Each visible parathyroid gland was scored 0, 1 or 2 depending on fluorescence intensity. Patients with at least one gland score of 2 were compared to those without. We measured PTH before and after TT, changes in calcium, creatinine and alanine transaminase (ALAT), postoperative alfacalcidol requirements, and adverse events of ICG use. Results: A total of 124 patients were included. Patients with at least one gland scored 2 ( n = 108) had a reduced need for alfacalcidol at discharge compared with those without (8% vs. 38%, p = 0.004), although hypoPT was not fully excluded. Six patients required alfacalcidol after 12 months and were classified as having permanent hypoPT; all had an intraoperative PTH decrease > 83%. Creatinine levels were higher in patients with permanent hypoPT compared to others ( p = 0.01). No increases in ALAT or ICG-related adverse events were observed. Conclusions: ICG-based parathyroid fluorescence during TT was well tolerated in this cohort and predicted immediate postoperative hypoPT. However, a fluorescence score of 2 did not exclude hypoPT development. The grading system is limited by subjectivity. No permanent hypoPT occurred in patients with a PTH decrease ≤ 83% after TT.
- 27 July 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Open AccessIndocyanine green fluorescence during total thyroidectomy: utility for predicting hypoparathyroidism and safety assessment
Purpose: Parathyroid fluorescence with indocyanine green (ICG) might prevent and predict postoperative hypoparathyroidism (hypoPT) after total thyroidectomy (TT). We aimed to evaluate parathyroid gland vascularization with ICG during TT. Further, we aimed to evaluate safety of ICG fluorescence and to correlate changes in PTH with postoperative hypoPT after TT. Methods: From May 2021 to June 2023, consecutive patients underwent TT and parathyroid fluorescence with ICG. Each visible parathyroid gland was scored 0, 1 or 2 depending on fluorescence intensity. Patients with at least one gland score of 2 were compared to those without. We measured PTH before and after TT, changes in calcium, creatinine and alanine transaminase (ALAT), postoperative alfacalcidol requirements, and adverse events of ICG use. Results: A total of 124 patients were included. Patients with at least one gland scored 2 ( n = 108) had a reduced need for alfacalcidol at discharge compared with those without (8% vs. 38%, p = 0.004), although hypoPT was not fully excluded. Six patients required alfacalcidol after 12 months and were classified as having permanent hypoPT; all had an intraoperative PTH decrease > 83%. Creatinine levels were higher in patients with permanent hypoPT compared to others ( p = 0.01). No increases in ALAT or ICG-related adverse events were observed. Conclusions: ICG-based parathyroid fluorescence during TT was well tolerated in this cohort and predicted immediate postoperative hypoPT. However, a fluorescence score of 2 did not exclude hypoPT development. The grading system is limited by subjectivity. No permanent hypoPT occurred in patients with a PTH decrease ≤ 83% after TT.
- Open Access
- 1 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (6) , R65-R88
Advances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders
The present report from the ESE Educational Program on Parathyroid Disorders (PARAT Program) presents recent developments and novelties in the clinical care of parathyroid disorders in a question-and-answer format, based on a satellite workshop held in relation to the European Congress of Endocrinology in Stockholm, May 2024. The workshop focused on clinical aspects of 3 main themes: primary hyperparathyroidism (PHPT), chronic hypoparathyroidism (HypoPT) in adults, and parathyroid disorders in pregnancy, with an emphasis on advances since the 2022 PARAT consensus report. The first section focuses on the long-term complications—including fractures, renal impairment, mental health, and quality of life—in patients with asymptomatic or mild forms of PHPT and on treatment strategies for syndromic PHPT (multiple endocrine neoplasia 1-4). In the latter, we explore appropriate surgical and non-surgical approaches, imaging techniques for gland localization, and preservation strategies in cases of multiglandular involvement. The second section addresses transient and partial forms of HypoPT in comparison to chronic and complete parathyroid hormone deficiency. It highlights the potential skeletal consequences of chronic HypoPT, the underlying etiologies, and discusses treatment modifications in light of the evolving therapeutic landscape. The final section, dedicated to the specific considerations of parathyroid disorders during pregnancy and lactation, focuses on pregnancy planning in patients with hereditary syndromic forms of PHPT, the differentiation between parathyroid-related and unrelated causes of hypercalcemia, and the associated risks for both mother and fetus. Additionally, it addresses the practical aspects of managing pregnant women with HypoPT, aiming to provide practical guidance for clinicians. Clinical vignettes featuring 3 cases illustrate common clinical situations.
- 1 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (6) , R65-R88
Open AccessAdvances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders
The present report from the ESE Educational Program on Parathyroid Disorders (PARAT Program) presents recent developments and novelties in the clinical care of parathyroid disorders in a question-and-answer format, based on a satellite workshop held in relation to the European Congress of Endocrinology in Stockholm, May 2024. The workshop focused on clinical aspects of 3 main themes: primary hyperparathyroidism (PHPT), chronic hypoparathyroidism (HypoPT) in adults, and parathyroid disorders in pregnancy, with an emphasis on advances since the 2022 PARAT consensus report. The first section focuses on the long-term complications—including fractures, renal impairment, mental health, and quality of life—in patients with asymptomatic or mild forms of PHPT and on treatment strategies for syndromic PHPT (multiple endocrine neoplasia 1-4). In the latter, we explore appropriate surgical and non-surgical approaches, imaging techniques for gland localization, and preservation strategies in cases of multiglandular involvement. The second section addresses transient and partial forms of HypoPT in comparison to chronic and complete parathyroid hormone deficiency. It highlights the potential skeletal consequences of chronic HypoPT, the underlying etiologies, and discusses treatment modifications in light of the evolving therapeutic landscape. The final section, dedicated to the specific considerations of parathyroid disorders during pregnancy and lactation, focuses on pregnancy planning in patients with hereditary syndromic forms of PHPT, the differentiation between parathyroid-related and unrelated causes of hypercalcemia, and the associated risks for both mother and fetus. Additionally, it addresses the practical aspects of managing pregnant women with HypoPT, aiming to provide practical guidance for clinicians. Clinical vignettes featuring 3 cases illustrate common clinical situations.
- Open Access
- 24 September 2025
- Published by Springer Nature in Updates in Surgery
- Vol. 77 (8) , 2205-2216
Unveiling publishing patterns in the European Society of Endocrine Surgeons congress abstracts: a retrospective multicentric publication analysis
Since 2004, the European Society of Endocrine Surgeons (ESES) has hosted biennial congresses as a platform for presenting key research. However, the publication rate of abstracts presented at these congresses is unknown. We searched for full publications using titles and authors of abstracts presented orally or as posters at ESES congresses from 2004 to 2018. Abstract factors, such as type of study and number of patients, were investigated in relation to publication rate, journal impact factor, and citation rates of published studies. Out of 733 abstracts presented at ESES during this period, 207 (28%) were presented orally and 528 (72%) as a poster, Overall, 456 of the abstracts (62%) were published, with a median time of 11.4 months from the ESES congress to publication [range − 64.5 to 156]. The median number of citations per published abstract was 21 [range 0–821], the average annual citation rate was 2.3 [0–54], and the median journal impact factor was 2.2 [0–21.3]. The median number of patients included per study was small, accounting for 71.5 [range 1–22,580]. While factors predicting higher chances for publication were oral format (OR 5), 2006 and 2008 ESES congresses (OR 21 and 12.6, respectively), larger sample sizes, oral presentation format, native English authorship, and randomized trials had higher annual citation rates. While the publication rates of ESES congress abstracts are high, collaborative efforts to conduct multicentric prospective studies could increase the publication rate of abstracts and enhance the overall scientific impact of the ESES congresses.
- 24 September 2025
- Published by Springer Nature in Updates in Surgery
- Vol. 77 (8) , 2205-2216
Open AccessUnveiling publishing patterns in the European Society of Endocrine Surgeons congress abstracts: a retrospective multicentric publication analysis
Since 2004, the European Society of Endocrine Surgeons (ESES) has hosted biennial congresses as a platform for presenting key research. However, the publication rate of abstracts presented at these congresses is unknown. We searched for full publications using titles and authors of abstracts presented orally or as posters at ESES congresses from 2004 to 2018. Abstract factors, such as type of study and number of patients, were investigated in relation to publication rate, journal impact factor, and citation rates of published studies. Out of 733 abstracts presented at ESES during this period, 207 (28%) were presented orally and 528 (72%) as a poster, Overall, 456 of the abstracts (62%) were published, with a median time of 11.4 months from the ESES congress to publication [range − 64.5 to 156]. The median number of citations per published abstract was 21 [range 0–821], the average annual citation rate was 2.3 [0–54], and the median journal impact factor was 2.2 [0–21.3]. The median number of patients included per study was small, accounting for 71.5 [range 1–22,580]. While factors predicting higher chances for publication were oral format (OR 5), 2006 and 2008 ESES congresses (OR 21 and 12.6, respectively), larger sample sizes, oral presentation format, native English authorship, and randomized trials had higher annual citation rates. While the publication rates of ESES congress abstracts are high, collaborative efforts to conduct multicentric prospective studies could increase the publication rate of abstracts and enhance the overall scientific impact of the ESES congresses.
- Open Access
- 7 May 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (3)
Perioperative characteristics and short-term morbidity after surgery for renal hyperparathyroidism: multicentre EUROCRINE® registry study
Background: Parathyroid surgery is an appropriate alternative for renal hyperparathyroidism (rHPT) in patients in whom medical therapy fails. European morbidity and outcome data for clearly defined cohorts, potentially reflecting contemporary clinical practice, remain scarce. Method: Data were extracted from the EUROCRINE® database on all operations for secondary rHPT between 1 January 2015 and 31 December 2021. Multivariable logistic regression analysis was used to identify risk factors for complications. Subgroup analyses were conducted for the two major surgical approaches (subtotal parathyroidectomy or total thyroidectomy with parathyroid transplantation), as well as for redo and concomitant thyroid surgery. The primary outcome was 30-day morbidity. Results: After excluding 324 patients, data were analysed for 1165 patients, who underwent primary surgery (859), redo surgery (135), or parathyroid surgery with concomitant (planned or unplanned) thyroid surgery (171). The postoperative complication rate was 13.8% (161 patients). Reintervention for bleeding was necessary in 22 patients (1.9%). The length of hospital stay was >1 week in 108 patients (9.8%), and was shorter in the redo parathyroidectomy than first-time parathyroidectomy group (52.0% (66) versus 36.6% (299) discharged within 2 days, respectively). No risk factors for complications could be identified in either the overall or subgroup analyses. In the case of redo surgery or primary surgery with concomitant thyroid surgery, recurrent laryngeal nerve palsy (6.7 versus 3.5%, respectively), revision surgery for bleeding (2.2 versus 1.2%, respectively), and wound infection rates (0.7 versus 0.0%, respectively) remained low. Conclusion: This large European multicentre cohort study demonstrates the safety and low morbidity of parathyroid surgery for rHPT.
- 7 May 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (3)
Open AccessPerioperative characteristics and short-term morbidity after surgery for renal hyperparathyroidism: multicentre EUROCRINE® registry study
Background: Parathyroid surgery is an appropriate alternative for renal hyperparathyroidism (rHPT) in patients in whom medical therapy fails. European morbidity and outcome data for clearly defined cohorts, potentially reflecting contemporary clinical practice, remain scarce. Method: Data were extracted from the EUROCRINE® database on all operations for secondary rHPT between 1 January 2015 and 31 December 2021. Multivariable logistic regression analysis was used to identify risk factors for complications. Subgroup analyses were conducted for the two major surgical approaches (subtotal parathyroidectomy or total thyroidectomy with parathyroid transplantation), as well as for redo and concomitant thyroid surgery. The primary outcome was 30-day morbidity. Results: After excluding 324 patients, data were analysed for 1165 patients, who underwent primary surgery (859), redo surgery (135), or parathyroid surgery with concomitant (planned or unplanned) thyroid surgery (171). The postoperative complication rate was 13.8% (161 patients). Reintervention for bleeding was necessary in 22 patients (1.9%). The length of hospital stay was >1 week in 108 patients (9.8%), and was shorter in the redo parathyroidectomy than first-time parathyroidectomy group (52.0% (66) versus 36.6% (299) discharged within 2 days, respectively). No risk factors for complications could be identified in either the overall or subgroup analyses. In the case of redo surgery or primary surgery with concomitant thyroid surgery, recurrent laryngeal nerve palsy (6.7 versus 3.5%, respectively), revision surgery for bleeding (2.2 versus 1.2%, respectively), and wound infection rates (0.7 versus 0.0%, respectively) remained low. Conclusion: This large European multicentre cohort study demonstrates the safety and low morbidity of parathyroid surgery for rHPT.
- 6 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , e1715
Response to Letter to the Editor From Candemir and Çakal: “24-Hour Urine Calcium Predicts Reduced Fracture Incidence and Improved Bone Mineral Density After Surgery for Primary Hyperparathyroidism”
- 6 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , e1715
Response to Letter to the Editor From Candemir and Çakal: “24-Hour Urine Calcium Predicts Reduced Fracture Incidence and Improved Bone Mineral Density After Surgery for Primary Hyperparathyroidism”
- 1 March 2025
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 151 (3) , 200
Shedding Light on How to Use Intraoperative Measurement of Parathyroid Hormone—Sunny Miami
- 1 March 2025
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 151 (3) , 200
Shedding Light on How to Use Intraoperative Measurement of Parathyroid Hormone—Sunny Miami
- 10 August 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , e1466-e1472
Increased Risk of Chronic Kidney Disease After Total Thyroidectomy: A Nationwide Matched Cohort Study
Background: Development of hypoparathyroidism (hypoPT) after total thyroidectomy (TT) may increase the risk of kidney-related morbidity. We aimed to examine the risk of hypoPT and chronic kidney disease (CKD) in patients undergoing TT in Denmark over a 20-year period. Materials and Methods: Using population-based registries, we identified all Danish individuals with TT between January 1998 and December 2017. We included a matched comparison cohort by randomly selecting 10 citizens for each patient by sex and birth year. We calculated the cumulative incidence and hazard ratio (HR) of CKD by Cox regression in patients with TT compared with the comparison cohort. Further, CKD risks were stratified by indications for TT and comorbidity groups according to the Charlson Comorbidity Index. Results: We included 2421 patients with TT; 21.5% had hypoPT. After 10 years, the risk of developing CKD for hypoPT patients was 13.5% [95% confidence interval (CI): 9.8-17.7], 11.6% (95% CI: 9.7-13.7) for patients without hypoPT, and 5.8% (95% CI: 5.3-6.2) for the comparison cohort. When compared with the matched comparison cohort, the adjusted HR for CKD in hypoPT patients was 3.23 (95% CI: 2.37–4.41) and 2.27 (95% CI: 1.87-2.75) for patients without hypoPT. For patients without previous comorbidities, the adjusted HR of CKD was higher than in patients with several comorbidities. Conclusion: HypoPT was a frequent complication after TT and was associated with an increased risk of CKD. We also found an increased risk of CKD in patients with a normal parathyroid function after TT, which needs to be further evaluated.
- 10 August 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , e1466-e1472
Increased Risk of Chronic Kidney Disease After Total Thyroidectomy: A Nationwide Matched Cohort Study
Background: Development of hypoparathyroidism (hypoPT) after total thyroidectomy (TT) may increase the risk of kidney-related morbidity. We aimed to examine the risk of hypoPT and chronic kidney disease (CKD) in patients undergoing TT in Denmark over a 20-year period. Materials and Methods: Using population-based registries, we identified all Danish individuals with TT between January 1998 and December 2017. We included a matched comparison cohort by randomly selecting 10 citizens for each patient by sex and birth year. We calculated the cumulative incidence and hazard ratio (HR) of CKD by Cox regression in patients with TT compared with the comparison cohort. Further, CKD risks were stratified by indications for TT and comorbidity groups according to the Charlson Comorbidity Index. Results: We included 2421 patients with TT; 21.5% had hypoPT. After 10 years, the risk of developing CKD for hypoPT patients was 13.5% [95% confidence interval (CI): 9.8-17.7], 11.6% (95% CI: 9.7-13.7) for patients without hypoPT, and 5.8% (95% CI: 5.3-6.2) for the comparison cohort. When compared with the matched comparison cohort, the adjusted HR for CKD in hypoPT patients was 3.23 (95% CI: 2.37–4.41) and 2.27 (95% CI: 1.87-2.75) for patients without hypoPT. For patients without previous comorbidities, the adjusted HR of CKD was higher than in patients with several comorbidities. Conclusion: HypoPT was a frequent complication after TT and was associated with an increased risk of CKD. We also found an increased risk of CKD in patients with a normal parathyroid function after TT, which needs to be further evaluated.
- Open Access
- 27 February 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (12) , e2273-e2282
24-hour Urine Calcium Predicts Reduced Fracture Incidence and Improved Bone Mineral Density After Surgery for Primary Hyperparathyroidism
Context: Contemporary patients with primary hyperparathyroidism are diagnosed with milder disease than previously. Clinical and biochemical factors predictors with an impact on fracture incidence and bone mineral density after surgery have not been firmly established. Objective: To investigate predictors of fracture incidence and bone mineral density preoperatively and after surgery for primary hyperparathyroidism (pHPT). Design: Prospectively collected surgical cohort with matched population controls. Data were cross-linked with the Swedish National Patient Register, the Prescribed Drug Register, and the Cause of Death Register. Setting: Tertiary referral center. Patients or other participants: Seven hundred nine patients with successful parathyroidectomy for pHPT and 2112 controls matched on sex, age, and municipality were included in the study. Main outcome measures: Fracture incidence, absolute change, and ≥2.77% increase in bone mineral density of femoral neck, L2–L4, and distal third of radius at 1-year follow-up. Results: Patients with pHPT had an increased fracture incidence before surgery but not after pHPT surgery. Fracture incidence after surgery was inversely related to preoperative 24-hour urine calcium (incidence rate ratio for the highest tertile 220– mg/d 0.29, 95% confidence interval 0.11-0.73). Serum and 24-hour urine calcium, parathyroid hormone, osteocalcin, and adenoma weight were all associated with bone mineral density recovery after surgery. Conclusion: Twenty-four-hour urine calcium is the most important biochemical variable to predict a decreased fracture incidence and improved bone mineral density after surgery for pHPT.
- 27 February 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (12) , e2273-e2282
Open Access24-hour Urine Calcium Predicts Reduced Fracture Incidence and Improved Bone Mineral Density After Surgery for Primary Hyperparathyroidism
Context: Contemporary patients with primary hyperparathyroidism are diagnosed with milder disease than previously. Clinical and biochemical factors predictors with an impact on fracture incidence and bone mineral density after surgery have not been firmly established. Objective: To investigate predictors of fracture incidence and bone mineral density preoperatively and after surgery for primary hyperparathyroidism (pHPT). Design: Prospectively collected surgical cohort with matched population controls. Data were cross-linked with the Swedish National Patient Register, the Prescribed Drug Register, and the Cause of Death Register. Setting: Tertiary referral center. Patients or other participants: Seven hundred nine patients with successful parathyroidectomy for pHPT and 2112 controls matched on sex, age, and municipality were included in the study. Main outcome measures: Fracture incidence, absolute change, and ≥2.77% increase in bone mineral density of femoral neck, L2–L4, and distal third of radius at 1-year follow-up. Results: Patients with pHPT had an increased fracture incidence before surgery but not after pHPT surgery. Fracture incidence after surgery was inversely related to preoperative 24-hour urine calcium (incidence rate ratio for the highest tertile 220– mg/d 0.29, 95% confidence interval 0.11-0.73). Serum and 24-hour urine calcium, parathyroid hormone, osteocalcin, and adenoma weight were all associated with bone mineral density recovery after surgery. Conclusion: Twenty-four-hour urine calcium is the most important biochemical variable to predict a decreased fracture incidence and improved bone mineral density after surgery for pHPT.
- Open Access
- 20 February 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 100 (4) , 408-415
Hypoparathyroidism and mortality after total thyroidectomy: A nationwide matched cohort study
Objective: Total thyroidectomy (TT) carries a risk of hypoparathyroidism (hypoPT). Recently, hypoPT has been associated with higher overall mortality rates. We aimed to evaluate the frequency of hypoPT and mortality in patients undergoing TT in Denmark covering 20 years.Design: Retrospective Cohort study.Patients and measurements: Using population‐based registries, we identified all Danish individuals who had undergone TT between January 1998 and December 2017. We included a comparison cohort by randomly selecting 10 citizens for each patient, matched on sex and birth year. HypoPT was defined as treatment with active vitamin D after 12 months postoperatively. We used cumulative incidence to calculate risks and Cox regression to compare the rate of mortality between patients and the comparison cohort. We evaluated patients in different comorbidity groups using the Charlson Comorbidity Index and by different indications for surgery.Results: 7912 patients underwent TT in the period. The prevalence of hypoPT in the study period was 16.6%, 12 months postoperatively. After adjusting for potential confounders the risk of death due to any causes (hazard ratio; 95% confidence intervals) following TT was significantly increased (1.34; 1.15‐1.56) for patients who developed hypoPT. However, subgroup analysis revealed mortality was only increased in malignancy cases (2.48; 1.99‐3.10) whereas mortality was not increased when surgery was due to benign indications such as goitre (0.88; 0.68‐1.15) or thyrotoxicosis (0.86; 0.57‐1.28).Conclusions: The use of active vitamin D for hypoPT was prevalent one year after TT. Patients with hypoPT did not have an increased risk of mortality following TT unless the indication was due to malignancy.
- 20 February 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 100 (4) , 408-415
Open AccessHypoparathyroidism and mortality after total thyroidectomy: A nationwide matched cohort study
Objective: Total thyroidectomy (TT) carries a risk of hypoparathyroidism (hypoPT). Recently, hypoPT has been associated with higher overall mortality rates. We aimed to evaluate the frequency of hypoPT and mortality in patients undergoing TT in Denmark covering 20 years.Design: Retrospective Cohort study.Patients and measurements: Using population‐based registries, we identified all Danish individuals who had undergone TT between January 1998 and December 2017. We included a comparison cohort by randomly selecting 10 citizens for each patient, matched on sex and birth year. HypoPT was defined as treatment with active vitamin D after 12 months postoperatively. We used cumulative incidence to calculate risks and Cox regression to compare the rate of mortality between patients and the comparison cohort. We evaluated patients in different comorbidity groups using the Charlson Comorbidity Index and by different indications for surgery.Results: 7912 patients underwent TT in the period. The prevalence of hypoPT in the study period was 16.6%, 12 months postoperatively. After adjusting for potential confounders the risk of death due to any causes (hazard ratio; 95% confidence intervals) following TT was significantly increased (1.34; 1.15‐1.56) for patients who developed hypoPT. However, subgroup analysis revealed mortality was only increased in malignancy cases (2.48; 1.99‐3.10) whereas mortality was not increased when surgery was due to benign indications such as goitre (0.88; 0.68‐1.15) or thyrotoxicosis (0.86; 0.57‐1.28).Conclusions: The use of active vitamin D for hypoPT was prevalent one year after TT. Patients with hypoPT did not have an increased risk of mortality following TT unless the indication was due to malignancy.